Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430788 | 0.92 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL14846448 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL9195578 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL8140042 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL15340724 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL13716189 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL29132046 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL7500053 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL26560361 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL12425238 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2734521-B1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| CN-101896481-A | Pyrimidyl indoline compound | DAIICHI SANKYO CO LTD | 2010-11-24 | — | — | CN | disclosed |
| US-7691558-B2 | Photosensitive composition, compound for use in the photosensitive composition and pattern forming method using the photosensitive composition | FUJIFILM CORPORATION (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | SMN1; SMN2 4351/4885NPC1 2135/4885RAB9A 221/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | SMN1; SMN2 4365/4885NPC1 861/4885RAB9A 3698/4885 |
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC2R, MC1R, MC3R | SMN1; SMN2 3279/4885NPC1 1425/4885RAB9A 2143/4885 |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | SMN1; SMN2 4062/4885NPC1 4558/4885RAB9A 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.